☰

Laura A. Boos, Ph.D. - Publications

Affiliations: 
2005 University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Immunology, Pathology
Tree Info Similar researchers PubMed Report error

3/16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2005 Boos L, Szalai AJ, Barnum SR. C3a expressed in the central nervous system protects against LPS-induced shock. Neuroscience Letters. 387: 68-71. PMID 16085360 DOI: 10.1016/J.Neulet.2005.07.015  0.526
2005 Boos LA, Szalai AJ, Barnum SR. Murine complement C4 is not required for experimental autoimmune encephalomyelitis. Glia. 49: 158-60. PMID 15390104 DOI: 10.1002/Glia.20093  0.47
2004 Boos L, Campbell IL, Ames R, Wetsel RA, Barnum SR. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 173: 4708-14. PMID 15383607 DOI: 10.4049/Jimmunol.173.7.4708  0.55
Low-probability matches (unlikely to be authored by this person)
2000 Deken SL, Beckman ML, Boos L, Quick MW. Transport rates of GABA transporters: regulation by the N-terminal domain and syntaxin 1A. Nature Neuroscience. 3: 998-1003. PMID 11017172 DOI: 10.1038/79939  0.184
2023 Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, et al. A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. Scientific Reports. 13: 3705. PMID 36879012 DOI: 10.1038/s41598-023-30950-z  0.11
2021 Fendler A, Au L, Shepherd S, Byrne F, Cerrone M, Boos L, Rzeniewicz K, Gordon W, Shum B, Gerard C, Ward B, Xie W, Schmitt A, Joharatnam-Hogan N, Cornish G, et al. Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Research Square. PMID 34580668 DOI: 10.21203/rs.3.rs-916427/v1  0.106
2021 Fendler A, Au L, Shepherd STC, Byrne F, Cerrone M, Boos LA, Rzeniewicz K, Gordon W, Shum B, Gerard CL, Ward B, Xie W, Schmitt AM, Joharatnam-Hogan N, Cornish GH, et al. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer. 2: 1321-1337. PMID 35121900 DOI: 10.1038/s43018-021-00275-9  0.104
2020 Comito F, Leslie I, Boos L, Furness A, Pickering L, Turajlic S, Larkin J. Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 32796274 DOI: 10.1097/CJI.0000000000000333  0.08
2020 Boos L, Leslie I, Larkin J. Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opinion On Investigational Drugs. PMID 32401070 DOI: 10.1080/13543784.2020.1769066  0.079
2021 Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, Tippu Z, Rzeniewicz K, Boos LA, Harvey R, Carlyle E, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer. 2: 1305-1320. PMID 35121899 DOI: 10.1038/s43018-021-00274-w  0.076
2020 Leslie I, Boos LA, Larkin J, Pickering L. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert Review of Anticancer Therapy. PMID 32293937 DOI: 10.1080/14737140.2020.1756780  0.074
2021 Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, Tippu Z, Rzeniewicz K, Boos LA, Harvey R, Carlyle E, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nature Cancer. 2: 1321-1337. PMID 34950880 DOI: 10.1038/s43018-021-00274-w  0.058
2020 Au L, Boos LA, Swerdlow A, Byrne F, Shepherd STC, Fendler A, Turajlic S. Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study. Cell. PMID 32979319 DOI: 10.1016/j.cell.2020.09.005  0.046
2015 Blank A, Wehweck L, Marinoni I, Boos LA, Bergmann F, Schmitt AM, Perren A. Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors. Virchows Archiv : An International Journal of Pathology. PMID 26384025 DOI: 10.1007/S00428-015-1843-3  0.042
2019 Boos LA, Schmitt A, Moch H, Komminoth P, Simillion C, Marinoni I, Nikiforov YE, Nikiforova MN, Perren A, Dettmer MS. MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma. Cancers. 11. PMID 31242620 DOI: 10.3390/cancers11060885  0.029
2013 Boos LA, Dettmer M, Schmitt A, Rudolph T, Steinert H, Moch H, Sobrinho-Simões M, Komminoth P, Perren A. Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases. Histopathology. 63: 234-41. PMID 23738683 DOI: 10.1111/his.12150  0.022
Hide low-probability matches.